A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
NCT ID: NCT05730725
Last Updated: 2025-11-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
109 participants
INTERVENTIONAL
2023-04-03
2024-08-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis
NCT02763969
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
NCT02931838
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
NCT00399906
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
NCT00162253
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
NCT03624127
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BMS-986322 Dose 1
BMS-986322
Specified dose on specified days
BMS-986322 Dose 2
BMS-986322
Specified dose on specified days
BMS-986322 Dose 3
BMS-986322
Specified dose on specified days
Placebo
Placebo
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986322
Specified dose on specified days
Placebo
Specified dose on specified days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index 18 to 40 kg/m\^2 and total body weight \> 50 kg (110 lbs)
* Deemed by Investigator to be eligible for phototherapy or systemic therapy
* Psoriatic plaques must cover ≥ 10% of body surface area at baseline
* Psoriasis Area and Severity Index (PASI) score ≥ 12 and static Physician Global Assessment (sPGA) ≥ 3 at baseline
Exclusion Criteria
* Diagnosis of uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with PsO for which a participant requires current systemic immunosuppressant medical treatment
* Any significant acute or chronic medical illness
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0006
Birmingham, Alabama, United States
Local Institution - 0012
Encino, California, United States
Local Institution - 0005
Fountain Valley, California, United States
Local Institution - 0002
Fremont, California, United States
Local Institution - 0001
Los Angeles, California, United States
Local Institution - 0016
Los Angeles, California, United States
Local Institution - 0003
Santa Ana, California, United States
Local Institution - 0013
Coral Gables, Florida, United States
Local Institution - 0056
Skokie, Illinois, United States
Local Institution - 0044
Clarksville, Indiana, United States
Local Institution - 0057
Leawood, Kansas, United States
Local Institution - 0004
Beverly, Massachusetts, United States
Local Institution - 0060
Lee's Summit, Missouri, United States
Local Institution - 0007
Portsmouth, New Hampshire, United States
Local Institution - 0055
Durham, North Carolina, United States
Local Institution - 0008
Cleveland, Ohio, United States
Local Institution - 0058
Rapid City, South Dakota, United States
Local Institution - 0059
Dallas, Texas, United States
Local Institution - 0011
Webster, Texas, United States
Local Institution - 0024
Brisbane, Queensland, Australia
Local Institution - 0019
Carlton, Victoria, Australia
Local Institution - 0045
Pascoe Vale South, Victoria, Australia
Local Institution - 0062
St. John's, Newfoundland and Labrador, Canada
Local Institution - 0034
Barrie, Ontario, Canada
Local Institution - 0020
Hamilton, Ontario, Canada
Local Institution - 0041
London, Ontario, Canada
Local Institution - 0030
Toronto, Ontario, Canada
Local Institution - 0049
Sapporo, Hokkaido, Japan
Local Institution - 0023
tabashi City, Tokyo, Japan
Local Institution - 0051
Fukuoka, , Japan
Local Institution - 0042
Itabashi-Ku, , Japan
Local Institution - 0026
Nagoya, , Japan
Local Institution - 0027
Tsu, , Japan
Local Institution - 0050
Hinckley, LEC, United Kingdom
Local Institution - 0046
Leytonstone, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-504848-34
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
U1111-1282-3606
Identifier Type: REGISTRY
Identifier Source: secondary_id
IM032-041
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.